TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma
TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma
复制标题
TRPV6是早期宫颈鳞状细胞癌的预后标志物
DOI：
10.1007/s13277-016-5368-4
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Yu YH
中科院分区：
文献类型：
--
作者：
Sun F;Xiao L;Jang XX;Xiong Y;Li Q;Yue XJ;Wei YJ;Wei YX;Ma YL;Yu YH
瞬时受体电位香草素6(TRPV6)已被证明在几种实体肿瘤中促进肿瘤增殖，导致不良的临床结果。本研究旨在探讨TRPV6在早期宫颈鳞癌(CSCC)中的临床意义。采用实时定量聚合酶链式反应(qRT-PCR)检测12对早期宫颈鳞癌组织和6株宫颈癌细胞株中TRPV6基因的表达。采用Western blotting和免疫组织化学(IHC)方法分别检测4例配对标本、175例早期宫颈鳞癌和50例正常宫颈组织中TRPV6的蛋白表达水平。对TRPV6表达的临床意义进行统计学分析。在早期宫颈鳞癌组织和宫颈癌细胞系中，TRPV6mRNA和蛋白的表达均显著下调。免疫组化分析显示，在175例早期宫颈鳞癌标本中，有136例(77.7%)TRPV6表达下调。此外，早期鳞癌中TRPV6的表达与肿瘤分期(P<；0.001)、肿瘤生长类型(P<；0.001)、肿瘤大小(P=0.008)和分化程度(P=0.003)显著相关。TRPV6低表达的早期CSCC患者无进展生存期(PFS)和总生存期(OS)较短。单变量和多变量分析证实TRPV6是影响早期CSCC患者生存的独立预后因素。我们发现TRPV6在CSCC中表达下调，这与早期CSCC患者的不良生存结局有关。TRPV6可作为早期宫颈鳞癌的一种新的预后指标。
Transient receptor potential vanilloid 6 (TRPV6) has been shown to promote caner proliferation in several solid tumors, leading to unfavorable clinical outcomes. Our study aimed to elucidate the clinical significance of TRPV6 in patients with early-stage cervical squamous cell carcinoma (CSCC). The mRNA expression of TRPV6 was measured in 12 paired early-stage CSCC specimens and six cervical carcinoma cell lines using quantitative real-time PCR (qRT-PCR). Western blotting and immunohistochemistry (IHC) were employed to examine the protein expression level of TRPV6 in four paired specimens, 175 paraffin-embedded early-stage CSCC specimens, and 50 normal cervical tissues (NCTs), respectively. Statistical analyses were performed to evaluate the clinical significance of TRPV6 expression. The expressions of TRPV6 mRNA and protein were both significantly downregulated in early-stage CSCC tissues and cervical cancer cell lines. IHC analyses revealed that TRPV6 was downregulated in 136 (77.7 %) of 175 early-stage CSCC specimens. Moreover, TRPV6 expression in early-stage CSCC was significantly correlated with the tumor stage (P < 0.001), tumor growth type (P < 0.001), tumor size (P = 0.008), and differentiation grade (P = 0.003). The early-stage CSCC patients with a low TRPV6 expression level had a short progress-free survival (PFS) and overall survival (OS) duration. Univariate and multivariate analyses identified TRPV6 as an independent prognostic factor for early-stage CSCC patients' survival. We demonstrated that TRPV6 was downregulated in CSCC, which was correlated with unfavorable survival outcomes of early-stage CSCC patients. TRPV6 may be used as a novel prognostic marker for early-stage CSCC.